RxDoctor Payments Data

Shawn Hall, MD

Family Medicine · Gonzales, LANPI 1306844147

Payments from drug & device makers

$5,495in general payments, 2019–2025

Across 371 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$1K
  • Astellas Pharma US Inc$515
  • Pfizer$439
  • Novo Nordisk$314
  • Amgen$279
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,45699%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,495 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$71,847
Medicare patients
226
Services billed
1,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide254$329,147
OzempicSemaglutide224$258,700
JardianceEmpagliflozin217$189,493
JanuviaSitagliptin Phosphate100$104,934
EliquisApixaban70$90,040
TrulicityDulaglutide31$58,093
MyrbetriqMirabegron65$43,602
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog39$43,527
XareltoRivaroxaban39$39,836
RybelsusSemaglutide29$33,057
Tresiba Flextouch U-200Insulin Degludec43$28,030
Xultophy 100-3.6Insulin Degludec/Liraglutide11$23,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$23,427
FarxigaDapagliflozin Propanediol29$23,044
Janumet XrSitagliptin Phos/Metformin Hcl21$21,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$122$387,240285 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$314$315,723264 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$57$214,779256 claims
MerckJanuvia, Janumet Xr$12$126,907121 claims
PfizerEliquis, Premarin$439$94,97388 claims
Astellas Pharma US IncMyrbetriq$515$43,60265 claims
Johnson & JohnsonXarelto$134$39,83639 claims
AstraZenecaFarxiga, Symbicort$67$32,09253 claims
GSKTrelegy Ellipta, Incruse Ellipta$1,094$27,76448 claims
AbbVieLinzess, Synthroid$1,060$27,337125 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$18$13,86812 claims
Esperion Therapeutics, Inc.Nexlizet$40$10,61923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Gonzales

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →